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Abstract
Extended-spectrum b-lactamase (ESBL)-producing Escherichia coli
isolates were detected in seven of 105 faecal samples from
healthy humans, from two Spanish cities, during 2007. In these
isolates, ﬁve ESBLs were detected, CTX-M-14 (n = 2), CTX-M-1
(n = 2), CTX-M-32 (n = 1), CTX-M-8 (n = 1) and TEM-52
(n = 1). Both blaCTX-M-14a (surrounded by ISEcp1-IS903) and
blaCTX-M-14b variants (included in an integron structure) were
identiﬁed in this study. This is the ﬁrst time that the blaCTX-M-8
gene and ESBLs of the CTX-M-8 group have been found in Eur-
ope and Spain, respectively. Faecal E. coli of healthy humans
therefore constitute a reservoir of blaCTX-M genes with different
surrounding genetic elements.
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A great increase in the prevalence of extended-spectrum
b-lactamases (ESBL) among clinical Escherichia coli isolates has
been observed worldwide in the last few years, with
CTX-M-producing E. coli especially prevalent as a cause of
community-acquired infections [1,2]. Faecal carriage of ESBL-
positive E. coli isolates has been reported in community and
hospital patients in only few studies [3–6]. In addition, ESBL-
positive E. coli isolates have also been found among healthy
and sick animals and also in food in various countries [7–10],
suggesting its spread in different ecosystems. Relatively few
data exist thus far on faecal colonization by ESBL-positive
E. coli isolates in healthy humans [4–6,11–13]. The objective
of our study was to characterize and determine the preva-
lence of ESBL genes in faecal E. coli isolates from healthy
humans, and to analyse the surrounding regions and their
possible inclusion into integrons.
Between March and October 2007, 105 faecal samples
were collected from healthy humans (age range 3–85 years)
living in two regions in the Centre and in the North of Spain,
Madrid (23 samples) and La Rioja (82 samples), respectively.
None of the individuals included in the study had been
exposed to antimicrobial agents or to a hospital environment
in the 3 months prior to sample recovery. Samples were
seeded onto Levine agar plates supplemented with cefo-
taxime (CTX, 2 lg/mL). After incubation at 37C for 48 h,
two colonies per sample showing E. coli morphology were
recovered, identiﬁed by classical biochemical methods and by
species-speciﬁc PCR (ampliﬁcation of uidA gene), and
screened for ESBL production according to CLSI criteria [14].
All ESBL-positive E. coli isolates obtained from this screen
were included in this study for further characterization. Sus-
ceptibility testing to 17 antimicrobials [ampicillin, amoxicillin-
clavulanic acid, cefoxitin, CTX, ceftazidime (CAZ), imipenem,
aztreonam, gentamicin, streptomycin, kanamycin, nalidixic
acid, ciproﬂoxacin, trimethoprim-sulfamethoxazole, sulphona-
mides, tetracycline, rifampicin and chloramphenicol] was per-
formed using the disc-diffusion and agar dilution methods
[14]. Genes encoding CTX-M, SHV, TEM, OXA and CMY
type b-lactamases, and the genetic environment of blaCTX-M
genes, were analysed by gene-speciﬁc PCR and DNA
sequencing [15]. The presence of class 1, 2 and 3 integrons,
as well as the characterization of the gene cassette arrange-
ments were studied by PCR and DNA sequencing [16]. The
presence of genes associated with tetracycline [tet(A)-tet(E),
tet(M)], streptomycin [aadA], sulphonamides [sul1, sul2, sul3],
kanamycin [aph(3¢)-Ia, aph(3¢)-IIa], and gentamicin resistance
[aac(3)-II, aac(3)-IV] were also analysed [16]. In addition,
amino acid changes in GyrA and ParC proteins were studied
by PCR and sequencing of the corresponding genes in quino-
lone-resistant isolates [16]. The identiﬁcation of the major
phylogenetic groups of ESBL-positive isolates was determined
by PCR [17].
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ESBL-producing E. coli isolates were detected in seven of
the 105 analysed faecal samples (6.6%). Two E. coli isolates
were recovered per positive sample, but only one of each
pair was kept for further studies due to the identical antimi-
crobial resistance phenotypes and ESBL genes exhibited by
both isolates. Table 1 shows the characteristics of the iso-
lates recovered from these positive samples. All of them
were found to be unrelated clonally when studied by repeti-
tive sequence-based PCR (data not shown). They presented
MIC values for CTX of >128 lg/mL and for CAZ from 1 to
>128 lg/mL. The ESBL genes found were blaCTX-M-14 (in two
isolates), blaCTX-M-1 (in two), blaCTX-M-32 (in one), blaCTX-M-8
(in one), and blaTEM-52 (in one). The blaCTX-M genes
detected in these isolates are included in three CTX-M
groups: blaCTX-M-14 in the CTX-M-9-group, blaCTX-M-1 and
blaCTX-M-32 in the CTX-M-1-group, and blaCTX-M-8 in the
CTX-M-8-group. All PCR tests performed to detect the
presence of other bla genes were negative.
According to previous reports, ESBLs of the CTX-M-8
group are very unusual in Europe and have been previously
detected in E. coli only in the UK, as the CTX-M-40 variant
[18], and never before in Spain.
An increase in the rate of ESBL-positive E. coli in commen-
sal microbiota of healthy children has been previously
observed in Latin America (0.1% in 2002 vs. 1.7% in 2005),
and diversiﬁcation of the type of CTX-M b-lactamases has
also been reported [13]. In 2003, levels of faecal colonization
by ESBL-positive E. coli isolates of 2.4% and 3.7% were found
in Lebanon [12] and Spain [4], respectively. The higher rate
found in our study (6.6% in 2007) is, however, less than that
recently detected in non-related healthy individuals in the
South of Spain (7.4%) [6] or in Saudi Arabia (13.1%) [5], and
less than the 16.7% and 27.4% detected in household con-
tacts of community patients in two further studies in Spain
[6,11]. The prevalence of faecal carriage of ESBL-positive
E. coli strains has signiﬁcantly increased in recent years, sug-
gesting that this is an emerging problem that is worsening
with time.
Different resistance phenotypes and genotypes were iden-
tiﬁed among the E. coli isolates studied. The tet(B), aadA,
sul1/sul2/sul3, aph(3¢)-Ia and aac(3)-II genes were found in
most of the tetracycline-, streptomycin-, sulfamethoxazole-,
kanamycin- and gentamicin-resistant ESBL-producing isolates.
Only the CTX-M-32-producing isolate showed ciproﬂoxacin
resistance and presented an unusual amino acid change in
GyrA (Ser83Leu and Ala84Pro), in addition to a change in
ParC (Ser80Ile). The B2 or D phylogenetic groups comprised
four of the isolates, and the remaining three isolates were
assigned to the A or B1 phylogenetic groups (Table 1).
The region surrounding the blaCTX-M genes detected in
our isolates is shown in Fig. 1. The blaCTX-M-14a genetic vari-
ant, ﬂanked by ISEcp1 and IS903 sequences, was found in
one of the isolates (Pn219), similar to isolates described in
previous reports [9,15,21]. Moreover, another isolate
(Pn138) possessed the unusual blaCTX-M-14b variant, included
into an In60 integron with a dfrA16 and aadA2 gene cassette
combination in its variable region and with the intI1 gene
truncated at the 3¢ end by the insertion of the IS26 element.
The integron-associated blaCTX-M-14b variant has been
described very recently in four human clinical E. coli isolates
in Spain and in Korea [19,20], but has not previously been
identiﬁed from faecal E. coli isolates from healthy humans.
The IS26/ISEcp1 and orf477 sequences were detected on
either side of the blaCTX-M-1 gene in two of our E. coli
TABLE 1. Characteristics of the seven extended-spectrum b-lactamase (ESBL)-positive Escherichia coli isolates recovered from
faecal samples of healthy humans
E. coli
isolatea
Type of
ESBL
Phylogenetic
group
MIC (lg/mL)
Resistance to non-b-lactams
Other genes
detectedb
Class 1 integron
Amino acid changes
inc
CTX CAZ intI1
Gene
cassettes GyrA ParC
Pn244-L CTX-M-1 B1 >128 4 STR
d aadA ) )
Pn248-L CTX-M-1 D >128 >128 STRd aadA ) )
Pn215-L CTX-M-8 A >128 1 TET–NAL tet (B) ) ) S83L Wild-type
Pn219-L CTX-M-14a B2 >128 2 TET–STR–SUL tet (B), sul2 ) )
Pn138-M CTX-M-14b D >128 >128 STRd–SXT–SUL sul1 )e dfrA16, aadA2
Pn137-M CTX-M-32 B2 >128 >128 STR–KAN–GEN–SUL–NAL–CIP aph(3¢)-Ia,
aac(3)-II, sul3
+ estX, psp,aadA2 S83L + A84P S80I
Pn357-L TEM-52 A >128 8 STRd ) ) )
CTX, cefotaxime; CAZ, ceftazidime; NAL, nalidixic acid; CIP, ciproﬂoxacin; GEN, gentamicin; KAN, kanamycin; STR, streptomycin; SUL, sulphonamides; SXT, trimethoprim-
sulfamethoxazole, TET, tetracycline.
aThe last letter of the isolate names shows the geographical origin of the samples: L, La Rioja and M, Madrid.
bDetected outside integron structure.
cAmino acid changes in GyrA and ParC have been studied only in quinolone-resistant isolates.
dIntermediate category according to the CLSI standards.
eThe intI1 gene is interrupted at the 3¢ end by the insertion of the IS26 element.
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isolates (Pn244 and Pn248); a similar arrangement has been
described by others [9,21]. In another isolate (Pn137), the
ISEcp1 truncated transposase and the IS5 sequence were
detected upstream of the blaCTX-M-32, and the orf477 down-
stream of this bla gene, as previously reported [22]. The sur-
rounding region of the blaCTX-M-8 gene could not be
identiﬁed. The blaCTX-M-32-positive isolate (Pn137) harboured
an unusual class 1 integron with the estX, psp, aadA2
arrangement in its variable region (Table 1), although we
could not demonstrate the inclusion of the ESBL gene inside
the integron structure.
In conclusion, a moderate prevalence and high diversity of
ESBLs were detected in faecal E. coli isolates of healthy
humans, mainly of the CTX-M type. This is remarkable as
the ﬁrst detection of CTX-M-8 group determinants in Spain,
and of the blaCTX-M-8 gene in Europe. The community could
be a reservoir of ESBL-producing E. coli isolates. This is the
ﬁrst time that the blaCTX-M-14 gene has been found included
into the In60 integron structure in commensal E. coli from
healthy humans.
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Abstract
Pneumocystis jirovecii causes severe pneumonia (PCP) in immuno-
compromised patients. Seasonal changes of PCP incidence may
be associated with climate changes. In this ﬁrst study using multi-
ple linear regression statistics to assess monthly climatic data
and Pneumocystis, PCP incidence was positively correlated with
mean temperature, but not with rainfall or wind strength.
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Pneumocystis jirovecii pneumonia (PCP) is one of the most fre-
quent and serious opportunistic infections. However, the
modes of transmission of PCP remain unknown. Air-borne
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